This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bionomics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Bionomics.

Wichtige Informationen

-36.0%

Wachstumsrate der Gewinne

-22.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	15.9%
Wachstumsrate der Einnahmen	-5.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	07 Aug 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

ASX:BNO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2025	5	-60	-21	N/A	2
6/30/2024	5	-39	-17	N/A	2
6/30/2023	5	-29	-20	N/A	2
12/31/2022	6	-25	-18	-18	N/A
9/30/2022	6	-23	-20	-20	N/A
6/30/2022	6	-22	-22	-22	N/A
3/31/2022	3	-22	-20	-20	N/A
12/31/2021	0	-22	-19	-19	N/A
9/30/2021	1	-15	-13	-13	N/A
6/30/2021	1	-9	-8	-8	N/A
3/31/2021	1	-4	N/A	N/A	N/A
12/31/2020	2	1	-5	-5	N/A
9/30/2020	2	-3	-5	-4	N/A
6/30/2020	3	-6	-4	-4	N/A
12/31/2019	6	-5	-9	-9	N/A
9/30/2019	7	-8	-13	-12	N/A
6/30/2019	7	-10	-16	-16	N/A
3/31/2019	8	-20	-15	-15	N/A
12/31/2018	8	-28	-15	-14	N/A
9/30/2018	10	-27	-18	-17	N/A
6/30/2018	12	-25	-21	-20	N/A
3/31/2018	19	-15	-16	-16	N/A
12/31/2017	27	-6	-11	-11	N/A
9/30/2017	27	-6	-6	-6	N/A
6/30/2017	27	-7	-2	-1	N/A
3/31/2017	22	-12	-7	-7	N/A
12/31/2016	16	-17	-13	-13	N/A
9/30/2016	18	-17	N/A	-14	N/A
6/30/2016	19	-17	N/A	-15	N/A
3/31/2016	19	-19	N/A	-17	N/A
12/31/2015	18	-21	N/A	-18	N/A
9/30/2015	17	-19	N/A	-6	N/A
6/30/2015	15	-17	N/A	5	N/A
3/31/2015	22	-6	N/A	6	N/A
12/31/2014	29	4	N/A	7	N/A
9/30/2014	28	4	N/A	-3	N/A
6/30/2014	27	3	N/A	-13	N/A
3/31/2014	19	-5	N/A	-9	N/A
12/31/2013	12	-13	N/A	-5	N/A
9/30/2013	12	-11	N/A	-8	N/A
6/30/2013	12	-10	N/A	-10	N/A
3/31/2013	13	-7	N/A	-9	N/A
12/31/2012	13	-4	N/A	-9	N/A
9/30/2012	12	-3	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BNO is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: BNO is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: BNO is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: BNO's revenue is expected to decline over the next 3 years (-5.3% per year).

Hohe Wachstumseinnahmen: BNO's revenue is forecast to decline over the next 3 years (-5.3% per year).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if BNO's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Bionomics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

New 90-day high: AU$0.39

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

New 90-day high: AU$0.22

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - AU$0.0082 loss per share

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken